{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:22:02Z","timestamp":1769750522267,"version":"3.49.0"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1097\/cad.0b013e328359d7ba","type":"journal-article","created":{"date-parts":[[2012,11,16]],"date-time":"2012-11-16T08:00:28Z","timestamp":1353052828000},"page":"99-111","source":"Crossref","is-referenced-by-count":16,"title":["Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors"],"prefix":"10.1097","volume":"24","author":[{"given":"Massimo","family":"Di Maio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Bria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe L.","family":"Banna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina C.","family":"Garassino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"Suppl 1","key":"R1-1-20210227","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.3747\/co.2008.171","article-title":"Chemotherapy- and cancer-related nausea and vomiting.","volume":"15","author":"Warr","year":"2008","journal-title":"Curr Oncol"},{"key":"R2-1-20210227","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.1997.15.1.103","article-title":"Proposal for classifying the acute emetogenicity of cancer chemotherapy.","volume":"15","author":"Hesketh","year":"1997","journal-title":"J Clin Oncol"},{"key":"R3-1-20210227","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","article-title":"Chemotherapy-induced nausea and vomiting.","volume":"358","author":"Hesketh","year":"2008","journal-title":"N Engl J Med"},{"key":"R4-1-20210227","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.1999.17.9.2971","article-title":"Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.","volume":"17","author":"Gralla","year":"1999","journal-title":"J Clin Oncol"},{"key":"R5-1-20210227","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1023\/A:1008256115221","article-title":"Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study.","volume":"9","author":"Goedhals","year":"1998","journal-title":"Ann Oncol"},{"key":"R7-1-20210227","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/bjc.1996.499","article-title":"Impact of tumour burden on chemotherapy-induced nausea and vomiting.","volume":"74","author":"Hursti","year":"1996","journal-title":"Br J Cancer"},{"key":"R8-1-20210227","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00520-009-0723-2","article-title":"Insight in the prediction of chemotherapy-induced nausea.","volume":"18","author":"Roscoe","year":"2010","journal-title":"Support Care Cancer"},{"key":"R9-1-20210227","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/1097-0142(19931001)72:7<2239::AID-CNCR2820720729>3.0.CO;2-5","article-title":"Urinary serotonin metabolite excretion during cisplatin chemotherapy.","volume":"72","author":"Wilder-Smith","year":"1993","journal-title":"Cancer"},{"key":"R10-1-20210227","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2165\/00003495-200060030-00002","article-title":"Potential of substance P antagonists as antiemetics.","volume":"60","author":"Diemunsch","year":"2000","journal-title":"Drugs"},{"issue":"s11","key":"R11-1-20210227","first-page":"18","article-title":"Imaging substance P receptors (NK1) in the living human brain using positron emission tomography.","volume":"63","author":"Hargreaves","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R12-1-20210227","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0277-5379(83)90418-2","article-title":"On the receiving end - patient perception of the side-effects of cancer chemotherapy.","volume":"19","author":"Coates","year":"1983","journal-title":"Eur J Cancer Clin Oncol"},{"key":"R13-1-20210227","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/oxfordjournals.annonc.a010548","article-title":"On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993.","volume":"7","author":"Griffin","year":"1996","journal-title":"Ann Oncol"},{"key":"R15-1-20210227","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1046\/j.1523-5394.1999.07205.x","article-title":"Perception of chemotherapy side effects cancer versus noncancer patients.","volume":"7","author":"Lindley","year":"1999","journal-title":"Cancer Pract"},{"key":"R16-1-20210227","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.1997.15.1.116","article-title":"Determinants of postchemotherapy nausea and vomiting in patients with cancer: Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.","volume":"15","author":"Osoba","year":"1997","journal-title":"J Clin Oncol"},{"key":"R17-1-20210227","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s005200050078","article-title":"Effect of postchemotherapy nausea and vomiting on health-related quality of life: The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.","volume":"5","author":"Osoba","year":"1997","journal-title":"Support Care Cancer"},{"key":"R18-1-20210227","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s005200050182","article-title":"The impact of postchemotherapy nausea and vomiting on quality of life after moderately emetogenic chemotherapy.","volume":"6","author":"Rusthoven","year":"1998","journal-title":"Support Care Cancer"},{"key":"R19-1-20210227","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","article-title":"Delayed nausea and vomiting continue to reduce patients quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.","volume":"24","author":"Bloechl-Daum","year":"2006","journal-title":"J Clin Oncol"},{"key":"R20-1-20210227","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s00520-004-0662-x","article-title":"Chemotherapy-induced nausea and vomiting in routine practice: a European perspective.","volume":"12","author":"Glaus","year":"2004","journal-title":"Support Care Cancer"},{"key":"R21-1-20210227","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00520-006-0109-7","article-title":"The impact of chemotherapy-induced nausea and vomiting on health-related quality of life.","volume":"15","author":"Ballatori","year":"2007","journal-title":"Support Care Cancer"},{"key":"R22-1-20210227","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cmonc.2011.11.001","article-title":"Treatment of chemotherapy-induced nausea.","volume":"9","author":"Navari","year":"2012","journal-title":"Community Oncol"},{"key":"R23-1-20210227","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejon.2007.10.002","article-title":"The impact of cancer and chemotherapy: perceptual similarities and differences between cancer patients, nurses and physicians.","volume":"12","author":"Mulders","year":"2008","journal-title":"Eur J Oncol Nurs"},{"key":"R24-1-20210227","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/cncr.20230","article-title":"Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.","volume":"100","author":"Grunberg","year":"2004","journal-title":"Cancer"},{"key":"R26-1-20210227","first-page":"857","article-title":"Evaluate the effects of implementing the Multinational Association of Supportive Care in Cancer (MASCC) antiemetic guideline on the incidence of chemotherapy-induced nausea and vomiting (CINV) following platinum chemotherapy. Proc MASCC 2009.","volume":"17","author":"OKane","year":"2009","journal-title":"Support Care Cancer"},{"key":"R27-1-20210227","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/annonc\/mds021","article-title":"The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).","volume":"23","author":"Aapro","year":"2012","journal-title":"Ann Oncol"},{"key":"R28-1-20210227","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update.","volume":"29","author":"Basch","year":"2011","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"R29-1-20210227","doi-asserted-by":"crossref","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","article-title":"Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.","volume":"21","author":"Roila","year":"2010","journal-title":"Ann Oncol"},{"key":"R31-1-20210227","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1200\/JCO.2006.06.9591","article-title":"American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.","volume":"24","author":"Kris","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"R32-1-20210227","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1007\/s00520-010-0976-9","article-title":"Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy.","volume":"19","author":"Kris","year":"2011","journal-title":"Support Care Cancer"},{"issue":"Suppl 1","key":"R33-1-20210227","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/s00520-010-0951-5","article-title":"Acute emesis: moderately emetogenic chemotherapy.","volume":"19","author":"Herrstedt","year":"2011","journal-title":"Support Care Cancer"},{"issue":"Suppl 1","key":"R34-1-20210227","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1007\/s00520-010-1039-y","article-title":"Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only).","volume":"19","author":"Roila","year":"2011","journal-title":"Support Care Cancer"},{"key":"R35-1-20210227","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","article-title":"Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.","volume":"10","author":"Saito","year":"2009","journal-title":"Lancet Oncol"},{"key":"R36-1-20210227","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/jnci\/djp177","article-title":"How much is life worth: cetuximab, non-small cell lung cancer, and the 440 billion question.","volume":"101","author":"Fojo","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 4","key":"R37-1-20210227","first-page":"38","article-title":"Cost-effective use of antiemetics.","volume":"12","author":"Grunberg","year":"1998","journal-title":"Oncology (Williston Park)"},{"key":"R39-1-20210227","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00520-006-0094-x","article-title":"The cost of chemotherapy-induced nausea and vomiting in Italy.","volume":"15","author":"Ballatori","year":"2007","journal-title":"Support Care Cancer"},{"key":"R40-1-20210227","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/annonc\/mdh110","article-title":"The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers.","volume":"15","author":"Ihbe-Heffinger","year":"2004","journal-title":"Ann Oncol"},{"key":"R41-1-20210227","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00520-009-0797-x","article-title":"Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting.","volume":"19","author":"Burke","year":"2011","journal-title":"Support Care Cancer"},{"key":"R42-1-20210227","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/cncr.22823","article-title":"Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy.","volume":"110","author":"Tina Shih","year":"2007","journal-title":"Cancer"},{"key":"R43-1-20210227","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","article-title":"The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group.","volume":"21","author":"Hesketh","year":"2003","journal-title":"J Clin Oncol"},{"key":"R44-1-20210227","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/cncr.11433","article-title":"Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America.","volume":"97","author":"Poli-Bigelli","year":"2003","journal-title":"Cancer"},{"key":"R45-1-20210227","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/annonc\/mdl019","article-title":"Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment.","volume":"17","author":"Schmoll","year":"2006","journal-title":"Ann Oncol"},{"key":"R46-1-20210227","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","article-title":"Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.","volume":"23","author":"Warr","year":"2005","journal-title":"J Clin Oncol"},{"key":"R47-1-20210227","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00520-009-0680-9","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.","volume":"18","author":"Rapoport","year":"2010","journal-title":"Support Care Cancer"},{"key":"R48-1-20210227","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1200\/JCO.2010.31.7859","article-title":"Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE.","volume":"29","author":"Grunberg","year":"2011","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"R49-1-20210227","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1007\/s00520-010-1003-x","article-title":"Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-state of the art.","volume":"19","author":"Grunberg","year":"2011","journal-title":"Support Care Cancer"},{"key":"R51-1-20210227","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0885-3924(00)00159-7","article-title":"Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy induced nausea and vomiting in 1413 patients treated in community clinical practices.","volume":"20","author":"Roscoe","year":"2000","journal-title":"J Pain Symptom Manage"},{"key":"R52-1-20210227","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10549-008-9957-9","article-title":"A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.","volume":"113","author":"Yeo","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"R53-1-20210227","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1002\/cncr.24630","article-title":"Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.","volume":"115","author":"Arpornwirat","year":"2009","journal-title":"Cancer"},{"key":"R54-1-20210227","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.2009.21.8511","article-title":"Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.","volume":"27","author":"Herrstedt","year":"2009","journal-title":"J Clin Oncol"},{"key":"R55-1-20210227","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1517\/14656566.2010.511615","article-title":"Advances in chemotherapy in advanced non-small-cell lung cancer.","volume":"11","author":"Maione","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"R56-1-20210227","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3816\/CLC.2010.n.040","article-title":"Second-line treatment for non-small-cell lung cancer: one size does not fit all.","volume":"11","author":"Caponi","year":"2010","journal-title":"Clin Lung Cancer"},{"key":"R58-1-20210227","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/jnci\/95.5.362","article-title":"Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung cancer in the Elderly Study (MILES) phase III randomized trial.","volume":"95","author":"Gridelli","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"R59-1-20210227","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ctrv.2010.05.004","article-title":"Second-line chemotherapy for small-cell lung cancer (SCLC).","volume":"37","author":"Kim","year":"2011","journal-title":"Cancer Treat Rev"},{"issue":"Suppl 8","key":"R60-1-20210227","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0959-8049(01)00267-2","article-title":"Cancer burden in the year 2000. The global picture.","volume":"37","author":"Parkin","year":"2001","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"R61-1-20210227","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/ijgc-00009577-200505001-00008","article-title":"Future options for first-line therapy of advanced ovarian cancer.","volume":"15","author":"Du Bois","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"R62-1-20210227","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1188\/02.CJON.94-102","article-title":"Chemotherapy-induced nausea and vomiting.","volume":"6","author":"Bender","year":"2002","journal-title":"Clin J Oncol Nurs"},{"key":"R63-1-20210227","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1037\/0033-2909.104.3.307","article-title":"Etiology and treatment of the psychological side effects associated with cancer chemotherapy: a critical review and discussion.","volume":"104","author":"Carey","year":"1988","journal-title":"Psychol Bull"},{"key":"R64-1-20210227","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3322\/canjclin.28.4.194","article-title":"Nausea, vomiting and cancer treatment.","volume":"28","author":"Harris","year":"1978","journal-title":"CA Cancer J Clin"},{"key":"R67-1-20210227","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0885-3924(02)00543-2","article-title":"Treatment of nausea and emesis during cancer chemotherapy. Discrepancies between antiemetic effect and well-being.","volume":"24","author":"Borjeson","year":"2002","journal-title":"J Pain Symptom Manage"},{"key":"R68-1-20210227","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00520-011-1180-2","article-title":"Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy.","volume":"20","author":"Hesketh","year":"2011","journal-title":"Support Care Cancer"},{"key":"R69-1-20210227","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s00520-011-1286-6","article-title":"Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy.","volume":"19","author":"Hesketh","year":"2011","journal-title":"Support Care Cancer"},{"key":"R70-1-20210227","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00520-011-1235-4","article-title":"Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study.","volume":"20","author":"Hesketh","year":"2012","journal-title":"Support Care Cancer"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0b013e328359d7ba","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:17:46Z","timestamp":1620947866000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001813-201302000-00001"}},"subtitle":["from guidelines to clinical practice in solid tumors"],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e328359d7ba","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}